Skip to main content
Premium Trial:

Request an Annual Quote

NCI's Cooperative Group Program Struggling to Subsist

A new National Institute of Medicine report says that the National Cancer Institute's Cooperative Group Program — a 50-year-old program that facilitates trials of new cancer treatments — is inefficient and lacks sufficient funding to continue operations as usual. John Mendelsohn of the MD Anderson Cancer Center told NPR's Richard Knox that the Cooperative Group Program is "at a breaking point," and that it "urgently needs changes across the board." Mendelsohn and 16 additional experts at IOM say that, in order to remain viable, the program's annual budget — currently $250 million — must double by 2015. "The panel also says it takes too long — two years on average — for the Cooperative Group to design, approve and launch a study," Knox writes. Katherine Hobson at the Wall Street Journal's Health Blog reports that IOM says the program should also "consolidate some administrative functions now handled by its 10 individual cooperative research groups and pay clinicians for designing and implementing the trials."

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.